- New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
- Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer
Bayer
announced today data from the Company’s evolving oncology portfolio
will be presented at the 2020 American Society of Clinical Oncology
Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15,
2020 in San Francisco, California. The presentations across the latest
research for Bayer’s marketed and pipeline therapies highlight the
company’s ongoing commitment to exploring the potential of its therapies
across different indications and treatment settings.
New data on the effect of Nubeqa®
(darolutamide) on cerebral blood flow compared to enzalutamide in men
with non-metastatic castration-resistant prostate cancer (nmCRPC) will
be presented. Nubeqa, an androgen receptor inhibitor (ARi) jointly
developed by Bayer and Orion Corporation, is approved in the U.S., Japan
and Brazil, and recently received a positive CHMP opinion in the
European Union (EU).
The
research presented from Bayer’s prostate cancer portfolio will also
include several presentations that feature real-world and combination
studies with Xofigo® (radium Ra 223 dichloride) in men with
certain types of prostate cancer. Among these is the first presentation
of investigational data from a randomized Phase II study of sipuleucel-T
(SipT) with or without Xofigo in men with asymptomatic metastatic
castration-resistant prostate cancer (mCRPC).
https://finance.yahoo.com/news/bayer-highlight-data-expanding-cancer-130000706.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.